-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $68

Benzinga·07/27/2026 12:45:34
Listen to the news
Wells Fargo analyst Benjamin Burnett initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $68.